JusticeFrance Official institution
France adds a generic version of REVESTIVE to its approved medicines list for public services
An order signed on 26 October 2026 and published in the Official Journal on 29 October adds TEDUGLUTIDE BIOGARAN, a generic of REVESTIVE, to the approved list. Its coverage follows the transparency commission's opinions on REVESTIVE, with prescribing limited to approved parenteral nutrition centres and renewed yearly.
Who is affected?
Patients who need parenteral nutrition, doctors at approved nutrition centres who prescribe it, and public bodies and services that use the approved medicines list.
What changes?
The order adds a prescribing framework for TEDUGLUTIDE BIOGARAN on the approved list; the exact changes are only in an annex not included in the source text.